CINECA IRIS Institutional Research Information System

VALERIO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.426
EU - Europa 2.418
AS - Asia 2.242
SA - Sud America 332
AF - Africa 179
Continente sconosciuto - Info sul continente non disponibili 160
OC - Oceania 9
Totale 9.766
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.303
IT - Italia 786
SG - Singapore 721
CN - Cina 602
DE - Germania 528
SE - Svezia 360
HK - Hong Kong 333
BR - Brasile 270
VN - Vietnam 185
GB - Regno Unito 178
BG - Bulgaria 131
FR - Francia 100
RU - Federazione Russa 86
CI - Costa d'Avorio 77
JP - Giappone 76
IN - India 75
CA - Canada 72
AT - Austria 68
TR - Turchia 60
FI - Finlandia 45
SN - Senegal 42
BD - Bangladesh 34
MA - Marocco 27
NL - Olanda 24
MX - Messico 23
PK - Pakistan 20
PL - Polonia 20
IQ - Iraq 19
AR - Argentina 18
KR - Corea 18
IR - Iran 15
ZA - Sudafrica 14
PH - Filippine 13
UZ - Uzbekistan 12
VE - Venezuela 12
ID - Indonesia 11
SA - Arabia Saudita 11
UA - Ucraina 11
BE - Belgio 9
CO - Colombia 9
EC - Ecuador 9
ES - Italia 9
AU - Australia 8
CZ - Repubblica Ceca 8
GR - Grecia 8
CR - Costa Rica 7
CH - Svizzera 6
UY - Uruguay 6
EG - Egitto 5
IE - Irlanda 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AL - Albania 4
CL - Cile 4
KZ - Kazakistan 4
LT - Lituania 4
NG - Nigeria 4
TN - Tunisia 4
TW - Taiwan 4
AZ - Azerbaigian 3
BH - Bahrain 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
JM - Giamaica 3
JO - Giordania 3
LB - Libano 3
MY - Malesia 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
IS - Islanda 2
KG - Kirghizistan 2
MM - Myanmar 2
MT - Malta 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
SV - El Salvador 2
A1 - Anonimo 1
EE - Estonia 1
GA - Gabon 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.608
Salva come PNG Salva come JPEG
Città #
Ashburn 585
Singapore 396
Hong Kong 325
Chandler 323
Dallas 320
Milan 295
San Jose 265
Fairfield 258
Santa Clara 242
Woodbridge 169
Houston 148
Seattle 134
Shanghai 130
Sofia 130
Wilmington 121
New York 118
Beijing 111
Los Angeles 102
Cambridge 96
Abidjan 77
Munich 74
Princeton 72
Ann Arbor 66
Vienna 62
London 61
Boardman 60
Tokyo 60
Ho Chi Minh City 55
Frankfurt am Main 53
Lauterbourg 52
Lawrence 51
Rome 51
Florence 43
Dakar 42
Medford 38
Pisa 34
Council Bluffs 32
Serra 31
Redwood City 30
Boulder 29
Dong Ket 25
Ottawa 25
São Paulo 25
Buffalo 23
Dearborn 22
Hanoi 22
Istanbul 22
Redmond 22
San Diego 22
Bremen 21
Helsinki 20
Redondo Beach 20
Washington 19
Hefei 18
Des Moines 17
Montreal 16
Phoenix 16
Atlanta 14
Fuzhou 14
Nuremberg 14
Belo Horizonte 13
Orem 13
Turku 13
Amsterdam 12
Scandicci 12
Toronto 12
Baghdad 11
Casablanca 11
Dhaka 11
Chiesina Uzzanese 10
Guangzhou 10
Nanjing 10
Quanzhou 10
Tashkent 10
Tianjin 10
Warsaw 10
Chicago 9
Denver 9
Düsseldorf 9
Izmir 9
Mumbai 9
San Francisco 9
Seoul 9
Zhengzhou 9
Brasília 8
Haiphong 8
Lancaster 8
Nanchang 8
Salt Lake City 8
Boston 7
Brussels 7
Roubaix 7
San José 7
Shenyang 7
Shenzhen 7
Columbus 6
Dublin 6
Jiaxing 6
Johannesburg 6
Kocaeli 6
Totale 6.100
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 246
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 245
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 238
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer 231
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 226
Targeted Therapy in Thyroid Cancer: State of the Art 225
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 220
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 218
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 214
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 213
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 210
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 207
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 199
Il carcinoma tiroideo: nuove prospettive terapeutiche. 193
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 190
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 189
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 179
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 178
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 172
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 171
Role of oxidative stress in radio-induced DNA damage and in RET/PTC rearrangement in papillary thyroid cancer 166
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 163
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 158
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 157
Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes 155
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 153
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 151
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 140
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 140
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 139
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 137
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 134
FDG-PET/CT Correlates with the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival 131
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 129
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 128
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 128
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 124
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 119
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 119
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 112
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 105
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study 104
Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination 94
null 84
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 55
Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study) 14
Totale 9.766
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.147
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.147
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022591 0 14 14 25 132 83 14 27 39 37 46 160
2022/20231.221 162 187 90 89 110 124 27 98 232 14 79 9
2023/2024922 91 118 133 85 144 154 29 20 10 11 44 83
2024/20252.031 11 65 22 120 212 214 163 88 196 255 188 497
2025/20262.556 227 356 270 213 292 167 387 112 181 217 83 51
2026/2027236 51 185 0 0 0 0 0 0 0 0 0 0
Totale 9.766